Stay updated on mRNA-4157 Vaccine and Pembrolizumab in Melanoma Clinical Trial.
Sign up to get notified when there's something new on the mRNA-4157 Vaccine and Pembrolizumab in Melanoma Clinical Trial. page.

Latest updates to the mRNA-4157 Vaccine and Pembrolizumab in Melanoma Clinical Trial. page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe page has been updated to reflect the latest version as v2.15.2, replacing the previous version v2.15.0. Additionally, the phrasing regarding the last update has been clarified.SummaryDifference0.1%
- Check15 days agoChange DetectedThe page has updated contact information for several oncology professionals, replacing some names and phone numbers while adding new contacts. Additionally, the last update date has been changed to reflect a more recent timeline.SummaryDifference3%
- Check23 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study descriptions and key inclusion/exclusion criteria for a clinical trial related to melanoma, while adding new terms such as 'Melanoma' and 'mRNA-4157-P201'.SummaryDifference16%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for March 13, 2025. However, there are no significant changes in core content, pricing, or availability.SummaryDifference0.3%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check52 days agoChange DetectedThe page has been updated to reflect a new contact number and email for the Moderna WeCare Team, as well as an increase in the number of study locations from 21 to 22, including specific details about a location in Atlanta, Georgia.SummaryDifference2%
Stay in the know with updates to mRNA-4157 Vaccine and Pembrolizumab in Melanoma Clinical Trial.
Enter your email address, and we'll notify you when there's something new on the mRNA-4157 Vaccine and Pembrolizumab in Melanoma Clinical Trial. page.